Top Line: One model to understand anthracycline cardiac toxicity is that it accelerates the normal aging process of cardiovascular structures.
The Study: Thus the theory of throwing statins at it. After all, “the pleiotropic cardiovascular protective effects of statins extend beyond lipid-lowering and include anti-inflammatory, antioxidant, and antifibrotic properties.” The double-blind randomized STOP-CA trial demonstrated adding atorvastatin 40 mg daily for patients receiving anthracyclines for lymphoma cut the odds of a clinically meaningful left ventricular ejection fraction decline in half. But anthracycline cardiotoxicity isn’t just about myocardium; it’s also about stiffening vasculature. This secondary analysis of enrollees with pre- and post-treatment cardiac MRIs evaluated statin impact on aortic stiffness. While aortic arch pulse wave velocity held steady in the first year for those on atorvastatin (mean 6.5→6.5 m/s), it rose significantly for those on placebo (5.7→6.8 m/s). Looked at another way, a ≥1 standard deviation increase occurred in just 5% on atorvastatin versus 50% on placebo (OR 0.05). Importantly, worsening aortic arch pulse wave velocity correlated with a modest but significant drop in ejection fraction—linking vascular and myocardial toxicity in the same patients. Next up: statins concurrent to mediastinal radiation..?
TBL: Beyond safeguarding ejection fraction, atorvastatin appears to keep anthracycline-exposed aortas from prematurely aging, strengthening the case that statins offer multifaceted cardioprotection during cardiotoxic chemo. | Juhasz, JAMA Cardiol 2025
The Study: Thus the theory of throwing statins at it. After all, “the pleiotropic cardiovascular protective effects of statins extend beyond lipid-lowering and include anti-inflammatory, antioxidant, and antifibrotic properties.” The double-blind randomized STOP-CA trial demonstrated adding atorvastatin 40 mg daily for patients receiving anthracyclines for lymphoma cut the odds of a clinically meaningful left ventricular ejection fraction decline in half. But anthracycline cardiotoxicity isn’t just about myocardium; it’s also about stiffening vasculature. This secondary analysis of enrollees with pre- and post-treatment cardiac MRIs evaluated statin impact on aortic stiffness. While aortic arch pulse wave velocity held steady in the first year for those on atorvastatin (mean 6.5→6.5 m/s), it rose significantly for those on placebo (5.7→6.8 m/s). Looked at another way, a ≥1 standard deviation increase occurred in just 5% on atorvastatin versus 50% on placebo (OR 0.05). Importantly, worsening aortic arch pulse wave velocity correlated with a modest but significant drop in ejection fraction—linking vascular and myocardial toxicity in the same patients. Next up: statins concurrent to mediastinal radiation..?
TBL: Beyond safeguarding ejection fraction, atorvastatin appears to keep anthracycline-exposed aortas from prematurely aging, strengthening the case that statins offer multifaceted cardioprotection during cardiotoxic chemo. | Juhasz, JAMA Cardiol 2025